MTM Thoulouzan

M Thoulouzan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M Thoulouzan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • A Pradines

    Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département "Innovation Thérapeutique et Oncologie Moléculaire", Institut Claudius Regaud, Toulouse, France

    1 shared publication
  • Carolyn Weinbaum

    Duke University, Medical Center Department of Pharmacology & Cancer Biology, Durham, NC, USA

    1 shared publication
  • Isabelle Lajoie-Mazenc

    Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département "Innovation Thérapeutique et Oncologie Moléculaire", Institut Claudius Regaud, Toulouse, France

    1 shared publication
  • Jc Faye

    Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département "Innovation Thérapeutique et Oncologie Moléculaire", Institut Claudius Regaud, Toulouse, France

    1 shared publication
  • M Goffinet

    Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département Innovation Thérapeutique et Oncologie Moléculaire, Institut Claudius Regaud, Toulouse, France

    1 shared publication
  • Sophie Séronie-Vivien

    Inserm U563, Centre de Physiopathologie de Toulouse Purpan, Département "Innovation Thérapeutique et Oncologie Moléculaire", Institut Claudius Regaud, Toulouse, France

    1 shared publication

Latest Publications

  • Open Access

    Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells

    by M Goffinet, M Thoulouzan, A Pradines, I Lajoie-Mazenc, Carolyn Weinbaum, Jc Faye, S Séronie-Vivien

    Background: Nitrogen-containing bisphosphonates (N-BPs) have been designed to inhibit osteoclast-mediated bone resorption. However, it is now accepted that part of their anti-tumor activities is related to interference with the mevalonate pathway.Methods: We investigated the effects of zoledronic acid (ZOL), on cell proliferation and protein isoprenylation in two tumoral (LnCAP, PC-3,), and one normal established (PNT1-A) prostatic cell line. To assess if inhibition of geranyl-geranylation by ZOL impairs the biological activity of RhoA GTPase, we studied the LPA-induced formation of stress fibers. The inhibitory effect of ZOL on geranyl geranyl transferase I was checked biochemically. Activity of ZOL on cholesterol biosynthesis was determined by measuring the incorporation of14C mevalonate in cholesterol.Results: ZOL induced dose-dependent inhibition of proliferation of all the three cell lines although it appeared more efficient on the untransformed PNT1A. Whatever the cell line, 20 μM ZOL-induced inhibition was reversed by geranyl-geraniol (GGOH) but neither by farnesol nor mevalonate. After 48 hours treatment of cells with 20 μM ZOL, geranyl-geranylation of Rap1A was abolished whereas farnesylation of HDJ-2 was unaffected. Inhibition of Rap1A geranyl-geranylation by ZOL was rescued by GGOH and not by FOH. Indeed, as observed with treatment by a geranyl-geranyl transferase inhibitor, treatment of PNT1-A cells with 20 μM ZOL prevented the LPA-induced formation of stress fibers. We checked that in vitro ZOL did not inhibit geranyl-geranyl-transferase I. ZOL strongly inhibited cholesterol biosynthesis up to 24 hours but at 48 hours 90% of this biosynthesis was rescued.Conclusion: Although zoledronic acid is currently the most efficient bisphosphonate in metastatic prostate cancer management, its mechanism of action in prostatic cells remains unclear. We suggest in this work that although in first intention ZOL inhibits FPPsynthase its main biological actitivity is directed against protein Geranylgeranylation.